Atossa Therapeutics, Inc. (ATOS)
NCM – Real vaqt narxi. Valyuta: USD
5.16
-0.34 (-6.18%)
Yopilishda: May 12, 2026, 4:00 PM EDT
5.36
+0.20 (3.88%)
Bozor oldidan: May 13, 2026, 7:03 AM EDT
Find any stock by ticker or company name

NCM – Real vaqt narxi. Valyuta: USD
5.16
-0.34 (-6.18%)
Yopilishda: May 12, 2026, 4:00 PM EDT
5.36
+0.20 (3.88%)
Bozor oldidan: May 13, 2026, 7:03 AM EDT
Atossa Therapeutics, Inc. - bu klinik bosqichdagi biofarmatsevtika kompaniyasi bo'lib, Qo'shma Shtatlarda onkologiya sohasida muhim tibbiy ehtiyojlarning sezilarli darajada qondirilmagan sohalarida dorilar ishlab chiqadi. Uning asosiy dori nomzodi og'iz orqali qabul qilinadigan (Z)-endoksifen bo'lib, u tanlangan estrogen retseptorlari modulyatori va tanlangan estrogen retseptorlari degradatori hisoblanadi va hozirda ko'krak bezi saratonini davolash va uning xavfini kamaytirish, shuningdek, boshqa terapevtik sohalarda 2-bosqichli klinik rivojlanishda. Kompaniya ilgari Atossa Genetics Inc. nomi bilan tanilgan va 2020-yil yanvar oyida Atossa Therapeutics, Inc. deb nomini o'zgartirgan. Atossa Therapeutics, Inc. 2008-yilda tashkil etilgan va Vashington shtatining Sietl shahrida joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Richard Graydon M.D., Ph.D. | Interim Chief Medical Officer |
| Dr. Steven C. Quay FCAP, M.D., Ph.D. | Chairman, CEO & President |
| Mr. Mark J. Daniel CPA | Chief Financial Officer |
| Ms. Delly Behen P.H.R. | Senior Vice President of Business Operations |
| Ms. Janet Rose Rea MSPH, RAC | Senior Vice President of Research & Development |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-05-08 | 8-K | atos-20260507.htm |
| 2026-05-08 | 10-Q | atos-20260331.htm |
| 2026-04-16 | 8-K | d107774d8k.htm |
| 2026-03-30 | ARS | ars_2025_10k_def_14a_202.pdf |
| 2026-03-25 | 8-K | atos-20260324.htm |
| 2026-03-25 | 10-K | atos-20251231.htm |
| 2026-03-20 | PRE 14A | atos-20260320.htm |
| 2026-02-20 | 8-K | d100198d8k.htm |
| 2026-02-17 | 8-K | atos-20260217.htm |
| 2026-02-11 | 8-K | atos-20260211.htm |